학술논문
Plasma cell–directed therapies in monoclonal gammopathy–associated scleromyxedema
Document Type
Article
Author
Mahévas, Thibault; Arnulf, Bertrand; Bouaziz, Jean-David; Livideanu, Cristina Bulai; Osio, Amélie; Servy, Amandine; Cribier, Bernard; Sassolas, Bruno; Jachiet, Marie; Michel, Laurence; Aucouturier, Pierre; Lipsker, Dan; Frances, Camille; Sbidian, Emilie; Rybojad, Michel; Descamps, Vincent; D'Incan, Michel; Humbert, Philippe; Beylot-Barry, Marie; Passeron, Thierry; de Moreuil, Claire; Taha, Ruba Y.; Hermine, Olivier; Dupuy, Alain; Barbarot, Sébastien; Debarbieux, Sébastien; Carpentier, Olivier; Brault, Fanny; Schmutz, Jean-Luc; Thomas-Beaulieu, Domitille; Modiano, Philippe; Zarnitsky, Charles; Lifermann, François; Baubion, Emilie; Limal, Nicolas; Le Bras, Fabien; Le Moigne, Marie; Tauber, Marie; Talbot, Alexis; Prud'homme, Romain; Peltier, Sandy; De Masson, Adèle; Battistella, Maxime; Bagot, Martine; Mékinian, Arsène; Fain, Olivier
Source
Blood; April 2020, Vol. 135 Issue: 14 p1101-1110, 10p
Subject
Language
ISSN
00064971; 15280020
Abstract
Scleromyxedema is a rare skin and systemic mucinosis that is usually associated with monoclonal gammopathy (MG). In this French multicenter retrospective study of 33 patients, we investigated the clinical and therapeutic features of MG-associated scleromyxedema. Skin molecular signatures were analyzed using a transcriptomic approach. Skin symptoms included papular eruptions (100%), sclerodermoid features (91%), and leonine facies (39%). MG involved an immunoglobulin G isotype in all patients, with a predominant λ light chain (73%). Associated hematologic malignancies were diagnosed in 4 of 33 patients (12%) (smoldering myeloma, n = 2; chronic lymphoid leukemia, n = 1; and refractory cytopenia with multilineage dysplasia, n = 1). Carpal tunnel syndrome (33%), arthralgia (25%), and dermato-neuro syndrome (DNS) (18%) were the most common systemic complications. One patient with mucinous cardiopathy died of acute heart failure. High-dose IV immunoglobulin (HDIVig), alone or in combination with steroids, appeared to be quite effective in nonsevere cases (clinical complete response achieved in 13/31 patients). Plasma cell–directed therapies using lenalidomide and/or bortezomib with dexamethasone and HDIVig led to a significant improvement in severe cases (HDIVig refractory or cases with central nervous system or cardiac involvement). The emergency treatment of DNS with combined plasmapheresis, HDIVig, and high-dose corticosteroids induced the complete remission of neurological symptoms in 4 of 5 patients. Quantitative reverse-transcriptase polymerase chain reaction analysis of 6 scleromyxedema skin samples showed significantly higher profibrotic pathway levels (transforming growth factor β and collagen-1) than in healthy skin. Prospective studies targeting plasma cell clones and/or fibrotic pathways are warranted for long-term scleromyxedema management.